



1635 JAL

PTO/SB/21 (02-04)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**TRANSMITTAL
FORM**

(to be used for all correspondence after initial filing)

Total Number of Pages in This Submission

Application Number	09/994,412
Filing Date	November 27, 2001
First Named Inventor	Ulrich Certa et al.
Art Unit	1635
Examiner Name	Karen A. Lacourciere
Attorney Docket Number	20787 US

ENCLOSURES (Check all that apply)

<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> After Allowance communication to Group
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Amendment/Reply	<input type="checkbox"/> Petition	<input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address	<input checked="" type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Terminal Disclaimer	<input type="checkbox"/> Other Enclosure(s) (please identify below):
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Request for Refund	
<input type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> CD, Number of CD(s) _____	
<input type="checkbox"/> Certified Copy of Priority Document(s)	Remarks	
<input type="checkbox"/> Response to Missing Parts/Incomplete Application		
<input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm or Individual name	Brian C. Remy
Signature	
Date	Sept. 22, 2004

CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.

Typed or printed name	Brian C. Remy		
Signature		Date	Sept. 22, 2004

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



PATENTS

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application: Ulrich Certa et al.

Group: 1635

Application No. 09/994,412

Examiner: Karen A. Lacourciere

Filed: November 27, 2001

Supervisory Examiner: John LeGuyader

For: **INHIBITION OF EXPRESSION OF A TARGET GENE**

STATUS INQUIRY

Nutley, New Jersey 07110
September 22, 2004

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Information regarding the present status of this application is respectfully requested.


The last communication from the Patent and Trademark Office was an Office Action dated October 1, 2003 which contained a restriction requirement. Applicants responded to this restriction requirement on October 29, 2003 (a copy of which is attached hereto). A copy of the document proving that the U.S.P.T.O. received this response on October 29, 2003 is also attached hereto in the form of an automatically generated return receipt confirmation of facsimile transmission from the U.S.P.T.O. Applicants have no record of any further communication from the Patent and Trademark Office and would appreciate knowing when a communication can be expected.

Respectfully submitted




Attorney for Applicant(s)
Brian C. Remy
(Reg. No. 48176)
340 Kingsland Street
Nutley, New Jersey 07110
Telephone: (973) 235-6516
Telefax: (973) 235-2363

BCR:ms
145997



Auto-Reply Facsimile Transmission



TO: Fax Sender at 973 235 2363
Fax Information
Date Received: 10/29/03 9:40:08 AM [Eastern Standard Time]
Total Pages: 4 (including cover page)

ADVISORY: This is an automatically generated return receipt confirmation of the facsimile transmission received by the Office. Please check to make sure that the number of pages listed as received in Total Pages above matches what was intended to be sent. Applicants are advised to retain this receipt in the unlikely event that proof of this facsimile transmission is necessary. Applicants are also advised to use the certificate of facsimile transmission procedures set forth in 37 CFR 1.8(a) and (b), 37 CFR 1.6(f). Trademark Applicants, also see the Trademark Manual of Examining Procedure (TMEP) section 306 et seq.

Received
Cover
Page
=====>

10/29/03 WED 10:42 FAX 973 235 2363		PATENT LAY	0001
<i>Fax Cover Sheet</i>			Pharmaceuticals
To:	Examiner Lacourciere Examiner, Art Unit 1635 Tel. 703-808-7523 Fax 703-872-9306		
Copies:			
From:	Lyman H. Smith Tel. 973-235-3916 Fax 973-235-2363		
Date:	October 29, 2003		
No. of pages:	4 (incl. cover sheet)		
<p>Please enter the attached response and forward to Examiner Lacourciere for consideration.</p> <p>Enclosed, please find:</p> <p>Response to Restriction Requirement (2 pages) Certificate of Transmission under 37 CFR 1.8 (1 page)</p>			
1/1			

Received from: 973 235 2363 at 10:29:41 10-29-03 09:40:08 AM Eastern Standard Time

Fax Cover Sheet

Roche

Pharmaceuticals

To: Examiner Lacourciere Examiner, Art Unit 1635
Tel. 703-308-7523
Fax 703-872-9306

Copies:

From: Lyman H. Smith
Tel. 973-235-3916
Fax 973-235-2363


Date: October 29, 2003

No. of pages: 4 (incl. cover sheet)

Please enter the attached response and forward to Examiner Lacourciere for consideration.

Enclosed, please find :

Response to Restriction Requirement (2 pages)
Certificate of Transmission under 37 CFR 1.8 (1 page)



Certificate of Transmission under 37 CFR 1.8

I hereby certify that this correspondence is being facsimile transmitted to the
United States Patent and Trademark Office (703-872-9306)

on October 29, 2003
Date




Signature

Lyman H. Smith

Typed or printed name of person signing Certificate

Note: Each paper must have its own certificate of transmission, or this certificate must identify each submitted paper.

Enclosed, please find :
Response to Restriction Requirement (2 pages)
Fee Transmittal Form (1 page)



PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application

Ulrich CERTA et al.

Group: 1635

Serial No. 09/994,412, filed November 27, 2001

Examiner: Karen A. Lacourciere

For: INHIBITION OF EXPRESSION OF A TARGET GENE

RESPONSE TO RESTRICTION REQUIREMENT

Nutley, New Jersey 07110
October 29, 2003

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In response to the requirement for restriction, dated as mailed on October 1, 2003, having a one-month shortened statutory period of response that expires on November 3, 2003, Applicants make the following election.


Applicants elect the invention of Group I, drawn to a process of inhibiting the expression of a target gene in cells or tissues. Group I includes claims 1-6.

If a telephone conference would be of assistance in furthering prosecution of the subject application, applicants request that the undersigned be contacted at the number below.

Serial No. 09/994,412
Filed: November 27, 2001

No fee is required in connection with the filing of this Amendment and Response. If any additional fees are deemed necessary, authorization is given to charge the amount of any such fee to Deposit Account No. 08-2525.

Respectfully submitted,



Agent for Applicant(s)
Lyman H. Smith
(Reg. No. 44,342)
340 Kingsland Street
Nutley, New Jersey 07110
Telephone: (973) 235-3916
Telefax: (973) 235-2363

135681